Supernus Pharmaceuticals ... (SUPN)
NASDAQ: SUPN
· Real-Time Price · USD
31.95
-0.33 (-1.02%)
At close: Jun 23, 2025, 3:59 PM
31.99
0.13%
After-hours: Jun 23, 2025, 04:04 PM EDT
-1.02% (1D)
Bid | 30.31 |
Market Cap | 1.79B |
Revenue (ttm) | 668M |
Net Income (ttm) | 61.91M |
EPS (ttm) | 1.11 |
PE Ratio (ttm) | 28.78 |
Forward PE | 13.18 |
Analyst | Hold |
Ask | 33.8 |
Volume | 639,223 |
Avg. Volume (20D) | 512,651 |
Open | 32.19 |
Previous Close | 32.28 |
Day's Range | 31.46 - 32.49 |
52-Week Range | 25.55 - 40.28 |
Beta | 0.71 |
About SUPN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SUPN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SUPN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Supernus Pharmaceuticals Inc. is scheduled to release its earnings on Aug 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-15.67%
Supernus Pharmaceuticals shares are trading lower ...
Unlock content with
Pro Subscription
4 months ago
+1.64%
Supernus Pharmaceuticals shares are trading lower after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.

1 month ago · seekingalpha.com
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call TranscriptSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Peter Vozzo - Investor Relations-ICR Healthcare Jack Khattar - Chief Executiv...